Market Research Logo

The Worldwide Market for Cancer Diagnostics, 4th Edition


Attention: There is an updated edition available for this report.

Since Kalorama Information last updated our comprehensive market report on cancer testing, changes in the industry abound. Developments that were novel two years ago such as the commercialization of service products , PGx testing and tissue microarrays are showing an increased presence. Some companies who promised much in the past have not produced results. And new entrants have entered the field.

These changes and more are addressed in Kalorama Information's Worldwide Market for Cancer Diagnostics, 4th. Edition. This report authored by Kalorama Diagnostic Analyst Shara Rosen, contains detailed market data on the following IVD segments for their use in cancer diagnostics:

  • Histology/Cytology
  • Immunoassays
  • Flow Cytometry
  • Rapid Tests
  • Molecular Assays
  • Tissue Arrays
  • Circulating Tumor Cells
  • Pharmacodiagnostics

Cancer Testing: A Dynamic Field

Given the unfortunate statistics of cancer in the developed world, innovation is a must. Growth rates in cancer testing tends to be higher than in other IVD fields. Diagnostic tests for effective cancer screening are obviously needed more than ever. As cancer becomes more treatable, diagnostics are finding multiple expanded roles, including pharmacodiagnostics for matching the targeted treatment to the patient and ongoing disease monitoring as treatable cancer enters the realm of the chronic disease. Often these tests are commercialized as test services, a trend explored in the report.

Cogent Analysis of Trends in the Industry

Kalorama Information reports are always based on primary research of the market with particular attention to important market trends that are more important to understand than today's numbers. Shara Rosen not only defines the marketplace and provides market numbers, but her report also examines trends that are driving cancer testing now and determining where it will go in the future. Some of the trends examined in this report include:

  • Biomarkers and Their Use in Cancer Testing
  • The Promise, and Reality of Personalized Medicine
  • Miniaturization and Multiplexed Biological Assays
  • The Emergence of Non-invasive tools
  • The Use of New Platforms: Mass Spectrometry Chromosome Analysis,
    Next-Generation Sequencing and RNA-based Tests
  • The In Vitro/In Vivo Mix
  • Global Screening Efforts and Their Impact on Testing Sales
  • Mergers and Partnerships in 2008 and 2009
  • Reimbursement for Cancer Tests
Based on an analysis of these trends, the report includes a 'Technology Forecast' to 2025 that takes each particular technology used now in solid tumor testing and predicts its future role.

Helpful Data Points for Business Planning

Kalorama Information's Worldwide Market for Cancer Diagnostics, 4th Edition represents the fourth time Kalorama has engaged in an exhaustive study on the status of this important diagnostic market. The report contains scores of tables with data points that can be useful for marketing strategy, product development or business forecasting. Here are a sampling of the data points readers could find in this report:

  • Sales of Immunoassay Lab-Based Tests (PSA, CEA, CA 125, AFP, Others) in 2009
  • The Number of Pap Smear Tests Conducted in the US.
  • World Incidence and Prevalence of Cancer Statistics
  • Point of Care Tests for Cancer
  • DNA Reagents for Cancer Testing
  • The Projections and Actual Results of CTC Test Products
  • The Needs of the Marketplace Not Met by Any Vendor
  • Innovative Biochip Products
  • A List of "Laggard" Companies Who Have Not Met Expectations
  • The Major Protein and Molecular Markers Used in Tissue Staining
  • Biomarkers Currently Under Investigation
  • Microarray Markets in Clinical Labs
  • Lists of Vendors and Major Products
Dualistic Market Analysis

This latest edition of Kalorama Information’s study takes a fresh look at all of these developments both qualitatively and quantitatively. The report provides revenue and growth forecasts through 2014 and, as in the previous edition, analyzes the market in two ways:

  • Tests for specific cancers, and
  • Cancer tests in specific IVD segments
This allows the reader to match his or her own situation to the market at large.

Unparalleled Review of Competitors: Top Tier IVDs, Status Quos and Novel Entrants

In addition to extensive reviews of products on the market and in development in each segment, the report provides detailed company profiles in three sections. The activities of the top IVD companies in cancer testing are presented in full, as are the activites of those 'status quo' companies who are leading in at least one segment. There is also coverage of the possible leaders of the future, the novel companies who have entered the market or developed a new approach. Companies profiled include the following:

Top Tier Companies
  • Abbott Diagnostics
  • Beckman Coulter Inc.
  • Becton, Dickinson and Company (BD)
  • bioMerieux Inc.
  • Bio-Rad Laboratories Inc.
  • Dako A/S
  • Fujirebio Diagnostics, Inc.
  • Gen-Probe Inc.
  • Hologic, Inc.
  • Inverness Medical Innovations
  • Ortho Clinical Diagnostics
  • QIAGEN N.V.
  • Roche Diagnostics
  • Siemens Medical Solutions Diagnostics
  • Sysmex Corporation
Status Quo Leader Companies
  • AdnaGen AG
  • Agendia BV
  • AMDL Diagnostics, Inc. (ADI)
  • American Diagnostica Inc.
  • Aperio Technologies, Inc.
  • Asuragen, Inc.
  • AviaraDx
  • Binding Site (The) Ltd.
  • BioCurex Inc.
  • BioGenex Laboratories, Inc.
  • BioImagene
  • Bio-Reference Laboratories, Inc.
  • Biotage AB
  • bioTheranostics
  • BioView Ltd.
  • Celera Diagnostics
  • China Medical Technologies, Inc.
  • Cisbio Bioassays
  • Clarient Inc. (formerly ChromaVision)
  • Clinical Data, Inc.
  • CytoCore, Inc.
  • DxS Ltd.
  • Epigenomics AG
  • Genetix Applied Imaging
  • Genomic Health, Inc.
  • Genzyme Genetics
  • Health Discovery Corporation
  • HistoRx, Inc.
  • Ikonisys, Inc.
  • Ipsogen SA
  • Lab21 Healthcare
  • Laboratory Corporation of America Holdings (LabCorp)
  • Life Technologies
  • Monogram Biosciences, Inc.
  • mtm laboratories AG
  • Myriad Genetics, Inc.
  • Nanosphere, Inc.
  • OncoVista Innovative Therapies, Inc.
  • Pathwork Diagnostics
  • Precision Therapeutics
  • Prometheus Laboratories Inc.
  • Quest Diagnostics
  • Response Genetics, Inc.
  • Rosetta Genomics Ltd.
  • Sequenom
  • Transgenomic Inc.
  • Veridex, LLC
  • Vermillion Inc.
  • Zila, Inc.
New Entrants
  • 20/20 GeneSystems, Inc.
  • 454 Life Sciences Corporation
  • Acrometrix Corporation (Life Tech.)
  • Acupath Laboratories, Inc.
  • Advalytix
  • Affymetrix, Inc.
  • Allegro Diagnostics
  • Althea Technologies, Inc.
  • Amorfix Life Sciences Ltd.
  • Arbor Vita Corporation
  • ArcticDx Inc.
  • Arrayit Diagnostics Inc.
  • AVEO Pharmaceuticals, Inc.
  • Axela, Inc.
  • Baypoint Biosystems, Inc.
  • Biodesix, Inc.
  • Biologix Diagnostics, LLC
  • BioMarker Strategies, LLC
  • Biomoda
  • BioMosaics
  • BioProspecting NB, Inc. (BPNBI)
  • BioServe
  • Biosystems International SAS (BSI)
  • BioTrove, Inc.
  • Cambridge Research & Instrumentation, Inc. (CRi)
  • Cangen Biotechnologies, Inc.
  • Caris Diagnostics
  • Castle Biosciences Inc.
  • Celerus Diagnostics
  • Cell Biosciences
  • CeMines, Inc.
  • Cepheid
  • ChromoCure Inc.
  • Chronix Biomedical Inc.
  • Clinical Genomics Pty Ltd.
  • CombiMatrix Molecular Diagnostics (CMDX)
  • Comprehensive Cancer Cell (CCC) Diagnostics Inc.
  • Compugen Ltd.
  • Correlogic Systems, Inc.
  • CS-Keys, Inc.
  • deCode Genetics Inc.
  • DiaGenic ASA
  • DiagnoCure --
  • Diagnoplex
  • Diagnostic Biosystems Company
  • DNA Direct, Inc.
  • DexTerity Diagnostics
  • EDP Biotech Corporation
  • Epistem Plc
  • Exact Sciences Corp.
  • Exiqon A/S
  • ExonHit Therapeutics
  • Exosome Diagnostics Inc.
  • Expression Pathology Inc.
  • Falcon Genomics, Inc.
  • FASgen Diagnostics, LLC
  • Fluxion Biosciences
  • Foligo Therapeutics, Inc.
  • Gastrocor
  • Genelex Corporation
  • GeneNews Limited
  • Genoptix
  • iKaryos Diagnostics
  • Illumina
  • Inostics GmbH
  • InteRNA Technologies B.V.
  • Intrinsic Bioprobes Inc.
  • Invirion Diagnostics, LLC
  • InVivoScribe Technologies
  • Iris BioTechnologies Inc.
  • IRIS International, Inc.
  • MabCure Inc.
  • MacroArray Technologies, LLC
  • MagArray Inc.
  • Martell Biosystems, Inc.
  • Med BioGene, Inc. (MBI)
  • Medical Prognosis Institute
  • Metabolon, Inc.
  • Miraculins Inc.
  • MolecularMD Corp.
  • Neogenix Oncology, Inc.
  • NextGen Sciences
  • Nuvera Biosciences
  • Olink AB
  • Oncimmune LLC
  • OncoMethylome Sciences S.A.
  • On-Q-ity
  • Orion Genomics
  • Oxford BioTherapeutics
  • Pacific Edge Biotechnology Ltd. (PEB)
  • Photocure ASA
  • Power3 Medical Products, Inc.
  • Prediction Sciences
  • Predictive Biosciences
  • PrognosDx Health, Inc.
  • Provista Life Sciences LLC
  • Rubicon Genomics, Inc.
  • Rules-Based Medicine, Inc. (RBM)
  • Saladax Biomedical, Inc. (SBI)
  • SensiGen LLC
  • Sienna Cancer Diagnostics
  • Signature Genomic Laboratories, LLC
  • Singulex Inc.
  • Skyline Diagnostics B.V.
  • Source MDx
  • Soar BioDynamics, Ltd.
  • Strategic Diagnostics Inc.
  • Synergenz Bioscience Ltd.
  • Targeted Molecular Diagnostics (TMD)
  • Theranostics Health (TH)
  • TrimGen Corporation
  • TrovaGene, Inc.
  • Vitatex Inc.
  • WaferGen Biosystems, Inc.
  • Xceed Molecular (formerly MetriGenix Corporation)
  • Zetiq Technologies Ltd.

All market data is based on factory sales to the end user and not retail pricing or reimbursement payments. For cancer testing, this means that the actual dollar market - that is what manufacturers earn from the sale of their products is undervalued. Market data is presented in dollar market size for categories of tests, and for specific analytes where possible.

The report discusses tests and technologies that are currently available and those that are expected to take their place. Generally, current products and technologies establish the standard of care and its value to payers. Many of the assays and imaging techniques presented in the report are expected to replace the standard of care in 2010, but with healthcare systems' emphasis on cost/benefit analysis for new technologies adoption, the market value and thus penetration capabilities of newer approaches may be limited.

The information presented in this report is derived on publicly available information sources such as company, government, and medical organization reports. The analysis is based on the author's industry knowledge combined with literature searches and interviews with industry professionals and experts in the areas of in vitro diagnostics, imaging industries and cancer specialists.


Biomarkers Seeing Increased, But Not Routine, use in Cancer Diagnostics

New biomarkers for cancer detection are emerging using several different approaches, and many of these technologies are still in the early phases of development. Protein and genetic biomarkers have long been celebrated as the future of personalized diagnostic medicine. They play an important role in detecting early forms of disease, in monitoring a patient’s disease and in response to therapy. However, biomarkers have a long way to go before they are routinely applied in clinical settings. The biomarkers below are the latest attempts:

  • Caveolin-1 The absence of stromal caveolin-1 has been associated with advanced tumor stage, early recurrence and metastasis of prostate and breast cancer.
  • Cotinine/NNAL Research has found that smokers with the highest urine levels of the tobacco metabolites: 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol (NNAL) and cotinine in their urine were 8.5 times more likely to develop the lung cancer. The researchers anticipate that the test could be used to motivate people to stop smoking.
  • Exosomes Exosomes are small microvesicles precipitously shed by all solid tumors into blood. They contain virtually the entire cancer tumor transcriptome.
  • Fibricytes Fibricytes are normal blood cells that play a role in healing wounds. They may also be cell promoters that help prepare distant tissue to accept metastasis.
  • Histones Histone modification patterns appear to have broad potential uses in the development of cancer prognostic assays including response predictions to therapeutics as well as research tools and reagents.
  • Midkine Blood midkine levels are greatly elevated in the early stages of cancer formation and poor prognosis for patients has also been closely linked to high midkine levels in a number of cancers.
  • Phosphorylation Determination of protein phosphorylation in blood or biopsied tissue specimens might replace biopsies for cancer diagnosis and response to treatment.
  • STAT3 The STAT3 protein has been found to play a major role in the change of normal cells into cancerous cells. STAT3, which has a role in the cell nucleus regulating gene expression.
Biomarkers are generally used in research, pharmaceutical clinical trials, and in treating special cases. A number of groups are working on the scientific and utilization foundations for new biomarker commercialization.

In April 2007, the American Association for Cancer Research (AACR), the Food and Drug Administration (FDA), and the National Cancer Institute (NCI) formed a collaboration aimed at creating a regulatory pathway for biomarkers that establishes guidelines for taking biomarkers from the research phase through the FDA approval process and then on to use in clinical laboratories.

The Cancer Biomarkers Collaborative (CBC) is focused on developing recommendations on assay validation and bioinformatics that would integrate biomarkers into drug development and clinical trials. This initiative is expected to provide the standardization needed for the use of new biomarkers in the clinical lab.

Personalized Medicine and Cancer Diagnostics

New York, April 27, 2010 — Cancer treatment is one area where the era of personalized medicine is arriving, according to market research publisher Kalorama Information. In its recent report The Worldwide Market for Cancer Diagnostics, Kalorama predicts a $90 million market for pharmacodiagnostics, tests that determine whether a treatment matches the individual patient, by 2014.

The information gleaned from the Human Genome Project and pharmacogenomics research by the drug industry is making possible individualized drug therapy based on the genetic make-up of a patient. The concept has been talked about for some time, but Kalorama notes in its biennial review of the cancer testing market that with five FDA approved test/treatment products, including tests for Herceptin, Gleevec, Erbitux, and Tarceva, and with many others in development, pharmacodiagnostics has moved beyond the concept phase.

“Personalized medicine is not occurring overnight, but it is occurring,” said Shara Rosen, lead diagnostic analyst for Kalorama Information. “More and more physicians are using these tests, and more Pharma companies are getting involved and looking to IVD companies for biomarker tools.”

The report says that while personalized medicine strategies are not new-it’s been eight years that Herceptin package inserts have labeled tests for therapy-responsive patients-the increase in drug/test development points towards greater utilization of these products. The market leaders are histopathology IVD companies Dako, Ventana Medical, Roche Diagnostics and Third Wave Technologies with FDA cleared tests. Oncotype DX was launched in the United States in 2004, where it has since been adopted as the standard of care for treating early-stage breast cancer. Oncotype DX is recommended in the guidelines of the American Society of Clinical Oncology (ASCO) and the National Comprehensive Cancer Network (NCCN), and is extensively reimbursed in the United States. Physicians use Oncotype DX to predict the likelihood of chemotherapy benefit, as well as the likelihood of recurrence, for patients with early stage breast cancer, in order to make individualized treatment decisions about the addition of chemotherapy to hormonal therapy.

By 2025, one in five new drugs could be labeled with a companion test, many of which will be cancer drugs, according to Kalorama. Many of the new companion tests are being developed as Dx-Rx partnerships. There are scores of Dx-Rx cancer co-development projects underway. Companies such as Qiagen/DxS (UK), MolecularMD (Portland, OR) and Roche/454 Life Sciences (Branford, CT) launched CE Marked test kits in 2008 and 2009. These tests are performed using blood instead of biopsied tissue.

Kalorama believes better-than-average growth levels will drive more companies to this area.

“This trend to personalized medicine is expected to create a huge market for cancer diagnostics in combination with the commercialization of the therapy,” Rosen said. “We expect pharmacogenomics, predisposition diagnostics and molecular diagnostics (PGx) to show 25 - 30% annual growth over the next 5-10 years.”

The report includes forecasts of several cancer testing market segments, detailed company profiles, trends and other information.

About Kalorama Information
Kalorama Information supplies the latest in independent market research in the life sciences, as well as a full range of custom research services.

  • Executive Summary
    • INTRODUCTION
    • SCOPE AND METHODOLOGY
    • SIZE AND GROWTH OF THE MARKET
      • Table Worldwide Market for Selected Cancer In Vitro Diagnostics, 2009-2014
      • Test Segments
      • Geographic Distribution
    • Market Trends
      • Death Rates
      • Revolutionary Therapeutics
      • Physician Factor
      • Consumer Lobby
      • Price
  • Introduction
    • Background
      • Pharmacogenomics
      • Test Service Commercialization
    • Cancer - Diagnosis And Therapy Management
    • Point Of View
  • Market Trends In The Commercialization Of Cancer Diagnostics
    • BACKGROUND
    • DEMOGRAPHICS OF CANCER, A GLOBAL PHENOMENON
    • CANCER TESTING IN THE WORLD
      • SCREENING AND GOVERNMENT SUPPORTED PROGRAMS
      • United States of America
      • International
      • Europe
        • Table Participation Rates of CRC Screening in National Programs and Pilot Studies
      • Mexico
      • China
      • India
    • REIMBURSEMENT AND COMMERCIALIZATION OF NOVEL TESTS
    • TEST SERVICES - ROUTE FOR CANCER INNOVATION
      • Table Selected Lab Service Cancer Tests Launched in 2008 & 2009
      • Table Selected CLIA-Certified Labs Established in 2008 & 2009
    • REGULATORY REQUIREMENTS OF NEW PRODUCTS
    • STRATEGIC ALLIANCES AND PARTNERSHIPS
      • Table Selected Acquisitions and Mergers, 2008-2009
      • Table Selected Company Alignments for Cancer Diagnostics, 2008-2009
    • PERSONALIZED MEDICINE ADVANCES
      • Table Selected Collaborations Between IVD and Pharmaceutical Companies, 2008-2009
    • GENE PATENTS AND TEST COMMERCIALIZATION
      • Table U.S. Patents for Selected Molecular Test Platforms
  • Technological Trends
    • BACKGROUND
    • BIOMARKER REVOLUTION
      • Table Selected Novel Biomarkers Under Investigation
    • THE PROMISE OF PERSONALIZED MEDICINE
    • MINIATURIZATION AND MULTIPLEXED BIOLOGICAL ASSAYS
      • Table Selected Biochip Test and Service Innovations, 2008-2009
    • THE EMERGENCE OF NON-INVASIVE TOOLS
      • Table Selected Innovations in Blood-Based Cancer Diagnostics, 2008-2009
      • Table Selected Non-Invasive Cancer Test Innovations, 2008-2009
    • NEW TECHNOLOGIES APPLIED TO CANCER DIAGNOSTICS
      • Overview
      • New Platforms
        • Table Selected Test Platform Innovations, 2008-2009
      • Mass Spectrometry
      • Chromosome Analysis
        • Table Selected Companies Involved in Chromosomal Analysis of Cancer Cells
      • Next-Generation Sequencing
      • RNA - Ribonucleic Acid
        • Table Selected RNA-based cancer tests
        • Table Selected Nucleic Acid Sample Preparation Products
    • THE IN VITRO/IN VIVO MIX
  • Market Analysis
    • BACKGROUND
    • WORLD REGIONAL SEGMENTS OF THE MARKET FOR CANCER DIAGNOSTICS
      • Table World Cancer Statistics, new cases per year
      • Table World Population, Cancer Patients and Percentage of Cancer Market IVD Statistics, 2005
      • Table World Cancer Test Sales, by Region, 2009-2014
    • COMPANIES AND PRODUCTS
      • Table Revenues of Selected Cancer Testing Companies
      • Table Selected Underperformers in the Cancer Market, 2008-2009
      • Table Cancer Diagnostics and the Top Tier of IVD Companies
    • HAS SCREENING LOST ITS ALLURE?
    • CANCER SPECIFIC TESTS
      • Bladder Cancer
      • Breast Cancer
        • Table Selected new histological breast cancer tests, 2008-2009
        • Table Selected Breast Cancer Test Innovations, 2008-2009
      • Cervical Cancer
        • Table Selected HPV test innovations, 2008-2009
      • Colon Cancer
        • Table Selected colon cancer test innovations, 2008-2009
        • Table Selected PGx tests for colon cancer, 2008-2009
      • Lung Cancer
        • Table Selected Lung Cancer Innovations, 2008-2009
      • Ovarian Cancer
        • Table Selected Ovarian Cancer Test Innovations, 2008-2009
      • Prostate Cancer
        • Table Selected Prostate Cancer Test Innovations, 2008-2009
  • Cancer Tests in IVD Segments
    • CANCER DIAGNOSTICS AND IVD MARKETS
      • Table Worldwide Market for Selected Cancer In Vitro Diagnostics (Histology/Cytology, Immunoassays, Flow Cytometry, Rapid Tests, Molecular Assays, Tissue Arrays, CTCs, Pharmacodiagnostics) 2009-2014
    • THE MARKET FOR CANCER TESTS IN CLINICAL CHEMISTRY
      • Table Selected Tissue Function Clinical Chemistry Tests
      • Table Major Players For Clinical Chemistry Analyzers And Reagents
    • THE MARKET FOR IMMUNOASSAY CANCER TESTS, LAB & RAPID
      • Table Selected Innovations in Cancer Immunoassays, 2008-2009
      • Table Cancer Immunoassay Sales, Lab-based, (PSA, CEA, CA 125, AFP, Others), 2009-2014
      • Point-of-care
        • Table Rapid Cancer Test Sales by Test Category (Fecal Occult Blood, PSA H Pylori, NMP22, Other), Worldwide 2009-2014
    • The Market for Cancer Tests in Histology / Cytology
      • Table Worldwide Histology/Cytology Sales (Traditional Non Pap, Pap, IHC, ISH, Image Cytometry, Tissue Micorarrays) 2009-2014
      • Traditional Tissue Stains
        • Table Selected Vendors of Traditional Histology Stains
      • Pap Smear and HPV Testing
        • Table Selected HPV Tests Innovations, 2008-2009
      • IHC/ISH
        • Table Major Protein and Molecular Markers Used in Tissue Staining
        • Table Selected Chromosome-Based Cancer Tests, 2008-2009
        • Table Selected Digital Imaging Innovations, 2008-2009
        • Table Selected Histopathology Innovations, 2008-2009
    • THE MARKET FOR TISSUE MICROARRAYS
      • Table Selected Tissue Microarray Products, 2008-2009
    • THE MARKET FOR CANCER TESTS IN FLOW CYTOMETRY
    • THE MARKET FOR CIRCULATING TUMOR CELLS IN CANCER DIAGNOSTICS
    • THE MARKET FOR CANCER MOLECULAR ASSAYS
      • Table Selected molecular Cancer Test Innovations, 2008-2009
    • THE MARKET FOR CANCER TESTS IN PHARMACODIAGNOSTICS
      • Table Selected Cancer PGx Test Innovations, 2008-2009
    • THE MARKET FOR BIOCHIPS AND ARRAYS IN CANCER DIAGNOSTICS
      • Table Selected Array-Based Cancer Test Innovations, 2008-2009
    • THE COMMERCIAL OUTLOOK FOR CANCER DIAGNOSTICS
      • Table Technology Penetration Forecast for Various IVD Technologies 2005-2025 (Minor Role, Moderate Role, Major Role, Rarely Used)
  • Conclusions
    • CONCLUSIONS AND STRATEGIC IMPLICATIONS
      • Conclusion 1
      • Conclusion 2
      • Conclusion 3
      • Conclusion 4
      • Conclusion 5
      • Conclusion 6
    • UNMET MARKET NEEDS
      • Unmet Need #1
      • Unmet Need #2
      • Unmet Need #3
  • The Top Tier of IVD Companies and their investment in cancer diagnostics
    • ABBOTT DIAGNOSTICS
      • Molecular Histology
      • Molecular Diagnostics
      • Immunoassays
    • BECKMAN COULTER INC.
      • FOB
      • Flow Cytometry
    • BECTON, DICKINSON AND COMPANY (BD)
      • Histology
    • BIOMERIEUX INC.
    • BIO-RAD LABORATORIES INC.
    • DAKO A/S
    • FUJIREBIO DIAGNOSTICS, INC.
    • GEN-PROBE INC.
    • HOLOGIC, INC.
      • Histology
      • HPV
    • INVERNESS MEDICAL INNOVATIONS
    • ORTHO CLINICAL DIAGNOSTICS
    • QIAGEN N.V.
    • ROCHE DIAGNOSTICS
      • Histology
      • Immunoassays
      • PCR
      • Research
    • SIEMENS MEDICAL SOLUTIONS DIAGNOSTICS
      • Molecular
      • In Vivo
    • SYSMEX CORPORATION
  • The Status Quo in Cancer Diagnostics
    • ADNAGEN AG
    • AGENDIA BV
    • AMDL DIAGNOSTICS, INC. (ADI)
    • AMERICAN DIAGNOSTICA INC.
    • APERIO TECHNOLOGIES, INC.
    • ASURAGEN, INC.
    • AVIARADX
    • BINDING SITE (THE) LTD.
    • BIOCUREX INC.
    • BIOGENEX LABORATORIES, INC.
    • BIOIMAGENE
    • BIO-REFERENCE LABORATORIES, INC.
    • BIOTAGE AB
    • BIOTHERANOSTICS
    • BIOVIEW LTD.
    • CELERA DIAGNOSTICS
    • CHINA MEDICAL TECHNOLOGIES, INC.
    • CISBIO BIOASSAYS
    • CLARIENT INC. (FORMERLY CHROMAVISION)
    • CLINICAL DATA, INC.
    • CYTOCORE, INC.
    • DXS LTD.
    • EPIGENOMICS AG
    • GENETIX APPLIED IMAGING
    • GENOMIC HEALTH, INC.
    • GENZYME GENETICS
    • HEALTH DISCOVERY CORPORATION
    • HISTORX, INC.
    • IKONISYS, INC.
    • INTERGENETICS INC.
    • IPSOGEN SA
    • LAB21 HEALTHCARE
    • LABORATORY CORPORATION OF AMERICA HOLDINGS LABCORP)
    • LIFE TECHNOLOGIES
    • MONOGRAM BIOSCIENCES, INC.
    • MTM LABORATORIES AG
    • MYRIAD GENETICS, INC.
    • NANOSPHERE, INC.
    • ONCOVISTA INNOVATIVE THERAPIES, INC.
    • PATHWORK DIAGNOSTICS
    • PRECISION THERAPEUTICS
    • PROMETHEUS LABORATORIES INC.
    • QUEST DIAGNOSTICS
    • RESPONSE GENETICS, INC.
    • ROSETTA GENOMICS LTD.
    • SEQUENOM
    • TRANSGENOMIC INC.
    • VERIDEX, LLC
    • VERMILLION INC.
    • ZILA, INC.
  • New Entrants And Novel Product Developers
    • 20/20 GeneSystems, Inc.
    • 454 Life Sciences Corporation
    • Acrometrix Corporation (Life Tech.)
    • Acupath Laboratories, Inc.
    • Advalytix
    • Affymetrix, Inc.
    • Allegro Diagnostics
    • Althea Technologies, Inc.
    • Amorfix Life Sciences Ltd.
    • Arbor Vita Corporation
    • ArcticDx Inc.
    • Arrayit Diagnostics Inc.
    • AVEO Pharmaceuticals, Inc.
    • Axela, Inc.
    • Baypoint Biosystems, Inc.
    • Biodesix, Inc.
    • Biologix Diagnostics, LLC
    • BioMarker Strategies, LLC
    • Biomoda
    • BioMosaics
    • BioProspecting NB, Inc. (BPNBI)
    • BioServe
    • Biosystems International SAS (BSI)
    • BioTrove, Inc.
    • Cambridge Research & Instrumentation, Inc. (CRi)
    • Cangen Biotechnologies, Inc.
    • Caris Diagnostics
    • Castle Biosciences Inc.
    • Celerus Diagnostics
    • Cell Biosciences
    • CeMines, Inc.
    • Cepheid
    • ChromoCure Inc.
    • Chronix Biomedical Inc.
    • Clinical Genomics Pty Ltd
    • CombiMatrix Molecular Diagnostics (CMDX)
    • Comprehensive Cancer Cell (CCC) Diagnostics Inc.
    • Compugen Ltd.
    • Correlogic Systems, Inc.
    • CS-Keys, Inc.
    • deCode Genetics Inc. ---
    • DiaGenic ASA
    • DiagnoCure --
    • Diagnoplex
    • Diagnostic Biosystems Company
    • DNA Direct, Inc.
    • DexTerity Diagnostics
    • EDP Biotech Corporation
    • Epistem Plc
    • Exact Sciences Corp.
    • Exiqon A/S
    • ExonHit Therapeutics
    • Exosome Diagnostics Inc.
    • Expression Pathology Inc.
    • Falcon Genomics, Inc.
    • FASgen Diagnostics, LLC
    • Fluxion Biosciences
    • Foligo Therapeutics, Inc.
    • Gastrocor
    • Genelex Corporation
    • GeneNews Limited
    • Genoptix
    • iKaryos Diagnostics
    • Illumina
    • Inostics GmbH
    • InteRNA Technologies B.V.
    • Intrinsic Bioprobes Inc.
    • Invirion Diagnostics, LLC
    • InVivoScribe Technologies
    • Iris BioTechnologies Inc.
    • IRIS International, Inc.
    • MabCure Inc.
    • MacroArray Technologies, LLC
    • MagArray Inc.
    • Martell Biosystems, Inc.
    • Med BioGene, Inc. (MBI)
    • Medical Prognosis Institute
    • Metabolon, Inc.
    • Miraculins Inc.
    • MolecularMD Corp.
    • Neogenix Oncology, Inc.
    • NextGen Sciences
    • Nuvera Biosciences
    • Olink AB
    • Oncimmune LLC
    • OncoMethylome Sciences S.A.
    • On-Q-ity
    • Orion Genomics
    • Oxford BioTherapeutics
    • Pacific Edge Biotechnology Ltd. (PEB)
    • Photocure ASA
    • Power3 Medical Products, Inc.
    • Prediction Sciences
    • Predictive Biosciences
    • PrognosDx Health, Inc.
    • Provista Life Sciences LLC
    • Rubicon Genomics, Inc.
    • Rules-Based Medicine, Inc. (RBM)
    • Saladax Biomedical, Inc. (SBI)
    • SensiGen LLC
    • Sienna Cancer Diagnostics
    • Signature Genomic Laboratories, LLC
    • Singulex Inc.
    • Skyline Diagnostics B.V.
    • Source MDx
    • Soar BioDynamics, Ltd.
    • Strategic Diagnostics Inc.
    • Synergenz Bioscience Ltd.
    • Targeted Molecular Diagnostics (TMD)
    • Theranostics Health (TH)
    • TrimGen Corporation
    • TrovaGene, Inc.
    • Vitatex Inc.
    • WaferGen Biosystems, Inc.
    • Xceed Molecular (formerly MetriGenix Corporation)
    • Zetiq Technologies Ltd.

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report